Advances in treatment of hyperkalemia in chronic kidney disease

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 14, 2015, Pages 2205-2215

  Sarafidis, Pantelis A ^a   Georgianos, Panagiotis I ^a   Bakris, George L ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

chronic kidney disease; hyperkalemia; patiromer; renin angiotensin aldosterone blockers; sodium zirconium cyclosilicate

Indexed keywords

PATIROMER; POTASSIUM; POTASSIUM CHANNEL AFFECTING AGENT; SODIUM ZIRCONIUM CYCLOSILICATE; POLYMER; POLYSTYRENE DERIVATIVE; POLYSTYRENESULFONIC ACID; SILICATE; ZS-9 COMPOUND;

CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; HEART FAILURE; HOMEOSTASIS; HUMAN; HYPERKALEMIA; POTASSIUM TRANSPORT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT WITHDRAWAL; BLOOD; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; RENAL INSUFFICIENCY, CHRONIC;

CLINICAL TRIALS AS TOPIC; HEART FAILURE; HOMEOSTASIS; HUMANS; HYPERKALEMIA; POLYMERS; POLYSTYRENES; POTASSIUM; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SILICATES;

EID: 84941423175     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1083977     Document Type: Review

References (66)

1. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009; 169 (12): 1156-62
2. Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012; 109 (10): 1510-13
3. Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol 2014; 10 (11): 653-62
4. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 2014; 34 (3): 333-9
5. Takaichi K, Takemoto F, Ubara Y, Mori Y. Analysis of factors causing hyperkalemia. Intern Med 2007; 46 (12): 823-9
6. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 2010; 5 (3): 531-48
7. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49 (1): 12-26
8. Sarafidis PA, Ruilope LM. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int 2014; 85 (3): 536-46
9. McGowan CE, Saha S, Chu G, et al. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J 2009; 102 (5): 493-7
10. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010; 21 (5): 733-5
11. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014; 312 (21): 2223-33
12. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015; 372 (3): 222-31
13. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372 (3): 211-21
14. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium reduction over 52 weeks in hyperkalemic patients with diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015; 314 (2): 151-61
15. Welling PA. Regulation of potassium channel trafficking in the distal nephron. Curr Opin Nephrol Hypertens 2013; 22 (5): 559-65
16. Welling PA. Regulation of renal potassium secretion: molecular mechanisms. Semin Nephrol 2013; 33 (3): 215-28
17. DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980; 17 (1): 118-34
18. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351 (6): 585-92
19. Simmons DH, Avedon M. Acid-base alterations and plasma potassium concentration. Am J Physiol 1959; 197: 319-26
20. Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. Int J Clin Pharm 2013; 35 (6): 1099-104
21. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000; 109: 307-14
22. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995; 98 (6): 575-86
23. Fenton F, Smally AJ, Laut J. Hyperkalemia and digoxin toxicity in a patient with kidney failure. Ann Emerg Med 1996; 28 (4): 440-1
24. Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ 2015; 187 (4): E138-43
25. Weir MA, Juurlink DN, Gomes T, et al. Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study. Clin J Am Soc Nephrol 2010; 5 (9): 1544-51
26. Drawz PE, Babineau DC, Rahman M. Metabolic complications in elderly adults with chronic kidney disease. J Am Geriatr Soc 2012; 60: 310-15
27. Drion I, Joosten H, Dikkeschei LD, et al. eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population. Eur J Intern Med 2009; 20: 722-7
28. Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009; 20 (1): 164-71
29. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 2012; 7 (8): 1234-41
30. Weinberg JM, Appel LJ, Bakris G, et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 2009; 169 (17): 1587-94
31. Brenner BM, Cooper ME, de ZD, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9
32. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329 (20): 1456-62
33. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-60
34. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. the angiotensin-converting-enzyme inhibition in progressive renal insufficiency study Group. N Engl J Med 1996; 334 (15): 939-45
35. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288 (19): 2421-31
36. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 2012; 30 (3): e156-66
37. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369 (20): 1892-903
38. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372 (9638): 547-53
39. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. N Engl J Med 2012; 367 (23): 2204-13
40. Sarafidis PA, Ruilope LM. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int 2014; 85 (3): 536-46
41. Buchner N, Banas B, Kramer BK. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 2008; 359 (4): 426
42. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66 (1): 1-9
43. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345 (12): 925-6
44. Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 2005; 28 (9): 2106-12
45. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70 (3): 536-42
46. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20 (12): 2641-50
47. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51 (2): 199-211
48. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30 (5): 418-24
49. Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012; 81 (10): 955-68
50. Roscioni SS, de ZD, Bakker SJ, Lambers Heerspink HJ. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol 2012; 8 (12): 691-9
51. Bakris G, Nowack C, Ruilope LM. Results of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes and diabetic nephropathy (Abstract). World Congress of Nephrology; CapeTown, South Africa: 2015
52. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (5 Suppl 2): 1-290
53. Zannad F, Gattis SW, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012; 33 (22): 2782-95
54. Keilani T, Danesh FR, Schlueter WA, et al. A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 1999; 33 (3): 450-7
55. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341 (10): 709-17
56. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364 (1): 11-21
57. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000; 58 (5): 2084-92
58. Zipser RD, Henrich WL. Implications of nonsteroidal anti-inflammatory drug therapy. Am J Med 1986; 80 (1A): 78-84
59. Marinella MA. Trimethoprim-induced hyperkalemia: An analysis of reported cases. Gerontology 1999; 45: 209-12
60. Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol 2014; 39 (2): 171-82
61. Chan CY, Peterson EJ, Ng TM. Thiazide diuretics as chronic antihypertensive therapy in patients with severe renal disease-is there a role in the absence of diuresis? Ann Pharmacother 2012; 46 (11): 1554-8
62. Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 2013; 126 (3): 264-24
63. Watson MA, Baker TP, Nguyen A, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am J Kidney Dis 2012; 60 (3): 409-16
64. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011; 32 (7): 820-8
65. Packham DK, Rasmussen HS, Singh B. New agents for hyperkalemia. N Engl J Med 2015; 372 (16): 1571-2
66. U.S. Renal Data System, USRDS 2013 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2014 ADR. 2013. Available from: http://www.usrds.org/2013/view/v1-05.aspx. [Last accessed 13 August 2015]